GlobeNewswire
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
📊
AI Sentiment
Positive
6/10
- Home
- PLRX
as of 12-02-2025 11:51am EST
$1.52
$0.02
-0.98%
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 93.3M | IPO Year: | 2020 |
| Target Price: | $3.79 | AVG Volume (30 days): | 762.4K |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $15.80 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -24.98% |
AI-Powered PLRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 73.83%
73.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
Compare PLRX vs Leading Stocks
See how PLRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.